Home › Bronchiolitis Obliterans Syndrome › Florida › Orlando
Bronchiolitis Obliterans Syndrome clinical trials in Orlando, FL
4 studies for Bronchiolitis Obliterans Syndrome are looking for participants at sites in and around Orlando (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)
RecruitingPhase 2
- Adventhealth Pediatric Cellular Therapy and Blood and Marrow Transplant, Orlando
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
RecruitingPhase 3
- Orlando Health Cancer Institute Downtown Orlando, Orlando
Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease
RecruitingObservational study
- AdventHealth Orlando, Orlando
- Moffit Cancer Center, Orlando
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
RecruitingPhase 2
- AdventHealth Orlando, Orlando
Bronchiolitis Obliterans Syndrome trials in other cities
- Boston, MA13 studies
- Seattle, WA11 studies
- Atlanta, GA10 studies
- New York City, NY9 studies
- Houston, TX8 studies
- Los Angeles, CA7 studies
- Miami, FL7 studies
- Tampa, FL6 studies
- Durham, NC6 studies
- Baldwin Park, CA6 studies
- Philadelphia, PA6 studies
- Washington, DC6 studies
Other studies in Orlando
- Non-Small Cell Lung Cancer44 studies
- Obesity32 studies
- Metastatic Cancer29 studies
- Overweight27 studies
- Alzheimer's Disease25 studies
- Type 2 Diabetes25 studies
- Cancer (all types)24 studies
- Breast Cancer23 studies
- Ovarian Cancer22 studies
- Ulcerative Colitis22 studies
- Lung Cancer21 studies
- Colorectal Cancer19 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.